Genetic Technologies Ltd. ADR (GENE): Price and Financial Metrics


Genetic Technologies Ltd. ADR (GENE): $1.14

0.00 (0.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GENE Stock Price Chart Interactive Chart >

Price chart for GENE

GENE Price/Volume Stats

Current price $1.14 52-week high $2.85
Prev. close $1.14 52-week low $0.95
Day low $1.11 Volume 16,900
Day high $1.16 Avg. volume 59,773
50-day MA $1.20 Dividend yield N/A
200-day MA $1.49 Market Cap 17.54M

Genetic Technologies Ltd. ADR (GENE) Company Bio


Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.


GENE Latest News Stream


Event/Time News Detail
Loading, please wait...

GENE Latest Social Stream


Loading social stream, please wait...

View Full GENE Social Stream

Latest GENE News From Around the Web

Below are the latest news stories about GENETIC TECHNOLOGIES LTD that investors may wish to consider to help them evaluate GENE as an investment opportunity.

Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth (PhD Director of Clinical & Scientific Affairs and GTG in the US) and Adjunct Professor Charles Siles Health (Executive Director and founder of Siles Health). A/Prof. Charles Siles, Obstetrician and Gynaecologist operates nine (9) clinics across Vic

Yahoo | November 10, 2022

Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation study evaluating the performance of the geneType ovarian cancer test. This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Canc

Yahoo | November 9, 2022

Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23). Q1 FY23 Highlights: Revenue from customers of A$1.93 million for the quarter, up 375% from prior corresponding period (Q1 FY22), highlighting commercial progress with revenues anchoring from GTG’s

Yahoo | October 25, 2022

Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 15, at 7 p.m. Eastern Time (ET).

Yahoo | October 13, 2022

Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician. Publication highlig

Yahoo | September 29, 2022

Read More 'GENE' Stories Here

GENE Price Returns

1-mo -5.00%
3-mo -24.00%
6-mo N/A
1-year -52.50%
3-year -39.60%
5-year -73.85%
YTD -39.36%
2021 -47.78%
2020 80.90%
2019 -9.54%
2018 -52.59%
2017 7.41%

Continue Researching GENE

Want to see what other sources are saying about Genetic Technologies Ltd's financials and stock price? Try the links below:

Genetic Technologies Ltd (GENE) Stock Price | Nasdaq
Genetic Technologies Ltd (GENE) Stock Quote, History and News - Yahoo Finance
Genetic Technologies Ltd (GENE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6919 seconds.